1. Home
  2. FPF vs CGEM Comparison

FPF vs CGEM Comparison

Compare FPF & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Trust Intermediate Duration Preferred & Income Fund of Beneficial Interest

FPF

First Trust Intermediate Duration Preferred & Income Fund of Beneficial Interest

N/A

Current Price

$17.91

Market Cap

1.1B

Sector

Finance

ML Signal

N/A

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

N/A

Current Price

$13.19

Market Cap

904.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FPF
CGEM
Founded
2013
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
904.7M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
FPF
CGEM
Price
$17.91
$13.19
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$30.13
AVG Volume (30 Days)
95.5K
1.0M
Earning Date
01-01-0001
05-11-2026
Dividend Yield
8.08%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$5.20
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$17.21
$5.68
52 Week High
$19.75
$16.74

Technical Indicators

Market Signals
Indicator
FPF
CGEM
Relative Strength Index (RSI) 40.33 37.35
Support Level $17.54 $11.92
Resistance Level $18.51 $13.21
Average True Range (ATR) 0.26 1.10
MACD -0.02 -0.26
Stochastic Oscillator 43.04 13.31

Price Performance

Historical Comparison
FPF
CGEM

About FPF First Trust Intermediate Duration Preferred & Income Fund of Beneficial Interest

First Trust Inter Dur Pref& Income Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek a high level of current income. Further, it has a secondary objective of capital appreciation. The Fund invests in the traditional preferred securities, hybrid preferred securities, floating rate & fixed-to-floating rate preferred securities, debt securities, convertible securities, and contingent convertible securities issued by U.S. and non-U.S. companies. Its investment portfolio includes industries such as Banks, Insurance, Capital Markets, Electric Utilities, Oil, Gas & Consumable Fuels, Food Products, and others.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Share on Social Networks: